secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monopar Therapeutics (MNPR)
CIK:        0001645469
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0001437749-25-026043
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monopar Q2 net loss $2.5M, cash $53.3M; ALXN1840 IND transferred, NDA plan for early 2026
--------------------------------------------------------------------------------

- Net loss $2.5M ($0.35/share) vs $1.7M ($0.49/share) in Q2 2024; R&D up $599k, G&A up $846k.
- Cash & equivalents $53.3M; company expects funds to support operations through Dec 2026.
- Alexion transferred IND for ALXN1840 (Wilson disease) on June 6, 2025; FDA acknowledged July 29.
- Monopar plans to submit NDA for ALXN1840 to FDA in early 2026.
- MNPR-101-Zr imaging trial and MNPR-101-Lu therapeutic trial active in Australia; Expanded Access Program enrolling in U.S.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645469/000143774925026043/0001437749-25-026043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645469/000143774925026043/mnpr20250807_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-026043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer